Abbott Laboratories reports second-quarter earnings on July 16, with investors focused on whether FreeStyle Libre sales growth remains above 20% and whether management raises full-year guidance. The continuous glucose monitoring platform generated roughly $2 billion in quarterly sales during the first quarter, serving more than 7 million users across over 60 countries. Abbott’s medical device segment, its largest growth engine, reached approximately $5.5 billion in first-quarter revenue, with the structural heart sub-segment contributing roughly $578 million from products like MitraClip and TriClip. The company also faces intense competition from DexCom in glucose monitoring and other device makers in cardiovascular care, but its diversified portfolio, 50-year dividend growth streak, and nearly $9.57 billion in 2025 free cash flow underpin a long-term investment case that may outweigh a single quarter’s results.
Abbott LaboratoriesArticle focuses on Abbott's upcoming earnings, with FreeStyle Libre growth and guidance as key factors; outcome unknown.
DexCom IncDexCom is mentioned as an intense competitor in glucose monitoring, but no specific news about DexCom itself.
NVIDIA Corporation